68Ga/177Lu-PSMA诊疗一体化在mCRPC随访中全身显像的价值
该研究基于68Ga-PSMA-11 PET/CT筛选32例mCRPC患者接受177Lu-PSMA-617治疗(6 GBq/周期,2-6周期),比较治疗后全身显像剂量学与PET/CT数据并分析生存。结果显示中位PFS 7个月、中位OS 12个月,PSA应答者中位OS 17个月优于非应答者11个月(p<0.05)。
要点
- 177Lu-PSMA-617首周期后骨骼转移灶肿瘤剂量较高(4.01±2.64 Gy/GBq)。
- 首周期后72%患者PSA下降,24h全身显像75%患者肿瘤/本底比值下降。
- PSA应答者中位OS 17个月,非应答者11个月(p<0.05)。
核心结论
- 系列PSA检测与治疗后24h全身显像可对177Lu-PSMA-617治疗的mCRPC患者进行足够准确的随访。
- 68Ga-PSMA-11 PET/CT应用于患者筛选和最终疗效评估。
研究设计与样本
- 基于68Ga-PSMA-11 PET/CT筛选32例连续mCRPC患者接受177Lu-PSMA-617治疗(6 GBq/周期,2至6周期,间隔6-10周),随访至死亡。
- 比较治疗后全身剂量学与68Ga-PSMA-11 PET/CT数据,并与无进展生存和总生存关联。
主要发现
- 首周期后177Lu-PSMA-617剂量学显示骨骼转移灶肿瘤剂量4.01±2.64 Gy/GBq(范围1.10-13.00),淋巴结转移灶3.12±2.07 Gy/GBq(范围0.70-8.70),肝转移灶2.97±1.38 Gy/GBq(范围0.76-5.00)。
- 首周期后23/32(72%)患者出现任何PSA下降,第二周期后22/32(69%),第三周期后16/28(57%),第四周期后8/18(44%)。
- 治疗后24h全身显像显示首周期后24/32(75%)患者肿瘤/本底比值下降,第二周期后17/29(59%),第三周期后13/21(62%)。
- 中位PFS为7个月,中位OS为12个月;PSA应答组(n=22)中位OS为17个月,非应答组(n=10)为11个月,p<0.05。
- 治疗后腮腺SUVmax由15.93±6.23降至12.33±4.07,颌下腺由17.65±7.34降至13.12±4.62,8/32(25%)患者出现暂时性(n=6)或永久性(n=2)口干。
关键数值与推荐
- 177Lu-PSMA-617给药活度为6 GBq/周期,2至6周期,间隔6-10周。
- 首周期后骨骼转移灶肿瘤剂量4.01±2.64 Gy/GBq,淋巴结3.12±2.07 Gy/GBq,肝脏2.97±1.38 Gy/GBq;组织/器官剂量在24 GBq意向治疗活度下所有患者可接受。
- 3/32患者肾毒性从2级变为3级,未发现4级肾毒性或血液毒性。
- 5/32(16%)患者显示混合应答模式,随时间推移出现疾病进展。
临床怎么用
- 可利用系列PSA检测联合治疗后24h全身显像对177Lu-PSMA-617治疗的mCRPC患者进行随访。
- 68Ga-PSMA-11 PET/CT用于治疗前患者筛选及最终疗效评估。
- 治疗后24h全身显像与PET/CT在示踪剂积聚视觉判读上多数患者一致性良好。
局限性
- 基线肿瘤吸收剂量与肿瘤病灶SUVmax之间未计算出显著性。
- 部分患者出现暂时性或永久性口干,以及肾毒性从2级变为3级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: A new therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) of heavily pre-treated patients lies in 177Lu-PSMA-617 radioligand therapy. METHODS: On the basis of PSMA-targeted 68Ga-PSMA-11 PET/CT, 32 consecutive mCRPC patients were selected for 177Lu-PSMA-617 therapy (6 GBq/cycle, 2 to 6 cycles, 6-10 weeks apart) and followed until death. Post-therapy whole-body (WB) dosimetry and 68Ga-PSMA-11 PET/CT data were compared and related to progression free and overall survival. RESULTS: 177Lu-PSMA-617 dosimetry after the first cycle indicated high tumor doses for skeletal (4.01 ± 2.64; range 1.10-13.00 Gy/GBq), lymph node (3.12 ± 2.07; range 0.70-8.70 Gy/GBq), and liver (2.97 ± 1.38; range 0.76-5.00 Gy/GBq) metastases whereas the dose for tissues/organs was acceptable in all patients for an intention-to-treat activity of 24 GBq. Any PSA decrease after the first cycle was found in 23/32 (72%), after the second cycle in 22/32 (69%), after the third cycle in 16/28 (57%), and after the fourth cycle in 8/18 (44%) patients. Post-therapy 24 h WB scintigraphy showed decreased tumor-to-background ratios in 24/32 (75%) after the first therapy cycle, after the second cycle in 17/29 (59%), and after the third cycle in 13/21 (62%) patients. The median PFS was 7 months and the median OS 12 months. In the group of PSA responders (n = 22) the median OS was 17 months versus 11 months in the group of non-responders (n = 10), p < 0.05. Decreasing SUVmax values were found for parotid (15.93 ± 6.23 versus 12.33 ± 4.07) and submandibular glands (17.65 ± 7.34 versus 13.12 ± 4.62) following treatment, along with transient (n = 6) or permanent (n = 2) xerostomia in 8/32 (25%) patients. In 3/32 patients, nephrotoxicity changed from Grade 2 to 3, whereas neither Grade 4 nephrotoxicity nor hematotoxicity was found. In most patients a good agreement was observed for the visual interpretation of the tracer accumulation between 24 h WB and PET/CT scans. However, no significance could be calculated for baseline-absorbed tumor doses and SUVmax values of tumor lesions. 5/32 (16%) patients showed a mixed response pattern, which resulted in disease progression over time. CONCLUSION: Serial PSA measurements and post-therapy 24 h WB scintigraphy seems to allow a sufficiently accurate follow-up of 177Lu-PSMA-617-treated mCRPC patients whereas 68Ga-PSMA-11 PET/CT should be performed for patient selection and final response assessment.
引用
- Maffey-Steffan J, Scarpa L, Svirydenka A, et al. The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up. Eur J Nucl Med Mol Imaging. 2019. PMID: 31776632. doi:10.1007/s00259-019-04583-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。